NLNathaniel M. Lewis

Nathaniel M. Lewis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nathaniel M. Lewis has a total of 570 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Influenza Vaccine Effectiveness Against Influenza A–Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, 2024–2025

    by Nathaniel M Lewis, Seana Cleary, Elizabeth J Harker, Basmah Safdar, Adit A Ginde, Ithan D Peltan, Manjusha Gaglani, Cristie Columbus, Emily T Martin, Adam S Lauring, et al.

    Background: The US 2024–2025 influenza season was characterized by sustained elevated activity from November 2024 to April 2025, with circulation of both influenza A(H1N1)pdm09 and A(H3N2), the latter of which included some antigenically drifted viruses. Methods: From 1 October 2024 to 30 April 2025, a multistate respiratory virus surveillance network enrolled adults hospitalized with acute respiratory illness in 26 US medical centers. Influenza vaccine effectiveness (VE) against influenza-associated hospitalization and severe in-hospital outcomes was estimated using a test-negative study. The odds of influenza vaccination among influenza-positive case patients and influenza-negative control patients were compared using multivariable logistic regression; VE was calculated as (1−adjusted odds ratio for vaccination) × 100, expressed as a percent. Results: The 2024–2025 seasonal influenza vaccine was effective against influenza-associated hospitalization (VE: 40% [95% confidence interval (CI): 32%–47%]), consistent across age group and influenza type/A subtype. Influenza vaccination also reduced the overall risk of all severe in-hospital outcomes evaluated, including standard oxygen therapy (VE: 41% [95% CI: 31%–50%]), noninvasive advanced respiratory support (VE: 38% [95% CI: 19%–52%]), invasive organ support (VE: 58% [95% CI: 44%–69%]), intensive care unit admission (VE: 58% [95% CI: 47%–67%]), and death (VE: 52% [95% CI: 18%–71%]) with effectiveness varying by influenza A subtype and age. Conclusions: Influenza vaccination reduced the risk of influenza-related hospitalization and severe in-hospital outcomes in adults during the severe 2024–2025 influenza season compared with those not vaccinated.

  • Differences in influenza vaccine effectiveness by sex among adults hospitalized with acute respiratory illness—IVY network, January 24, 2022–September 1, 2024

    by Elizabeth J. Harker, Nathaniel M. Lewis, Cassandra A. Johnson, Yuwei Zhu, Wesley H. Self, Natasha Halasa, James D. Chappell, Carlos G. Grijalva, Basmah Safdar, Manju Gaglani, et al.


  • Severity of Clinical Presentation and Outcomes in Hospitalized Adult People With Influenza by Type and Subtype, United States—2017–2020

    by Seana Cleary, Nathaniel M Lewis, H Keipp Talbot, Yuwei Zhu, Emily T Martin, Arnold S Monto, Manjusha Gaglani, Kempapura Murthy, Richard K Zimmerman, Fernanda P Silveira, et al.

    Background: While influenza A(H3N2)-predominant seasons tend to have increased rates of influenza-associated hospitalizations and deaths, little is known about differences in clinical presentation and hospitalization outcomes by influenza type and subtype. Methods: Data from hospitalized adults aged ≥18 years in 4 US states from 2017 to 2020 were used to evaluate the association between influenza type/subtype and severe influenza presentation and outcomes. Log binomial regression and modified Poisson regression with robust error variance were used to estimate adjusted risk ratios (aRRs) for clinical indicators within 24 hours of hospital admission and severity outcomes. Multivariable Cox proportional hazard models were used to estimate adjusted hazard ratios for length of hospital stay and intensive care unit (ICU) stay. All models were adjusted for underlying conditions, age group, influenza vaccination, and site. Results: People with influenza A(H1N1) were more likely to be admitted to an ICU (aRR = 1.42) than people with A(H3N2). People with influenza A(H1N1) had higher risk of hypoxemia (SpO2 38°C, aRR = 1.56). Conclusions: Adult people hospitalized with influenza A(H1N1) had a higher risk of multiple severity indicators. Better understanding of influenza severity related to both host and virus type is important for reducing the burden of severe influenza in adults.


  • Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus

    by Kevin C Ma, Diya Surie, Yuwei Zhu, Carlos G Grijalva, Paul W Blair, Basmah Safdar, Adit A Ginde, Ithan D Peltan, Samuel M Brown, Manjusha Gaglani, et al.

    Background: Adults hospitalized with acute respiratory infections, including respiratory syncytial virus (RSV), often have multiple underlying conditions. Few data are available on the combined effect of conditions on risk of severe outcomes from RSV disease. Methods: We enrolled adults hospitalized with RSV at 26 hospitals in 20 US states admitted January 2022–July 2024. Seventeen underlying conditions were selected after excluding those with rare prevalence (≤1%) or high pairwise correlation (≥0.7). We applied Bayesian profile regression to identify profiles of conditions associated with increased risk of RSV severe outcomes, stratifying among adults aged 18–59 and ≥60 years. Results: We analyzed data from 1111 adults hospitalized with RSV (median [IQR] age, 66 [53–75] years). Among 397 adults aged 18–59 years, 2 profiles were identified: (1) minimal prevalence with fewer underlying conditions and a posterior median intensive care unit (ICU) admission risk of 21% (95% credible interval, 16%–25%) and (2) cardiorenal/diabetes with frequent heart failure, chronic kidney disease, diabetes, and increased ICU admission risk (37% [27%–48%]). Among 714 adults aged 60 years and older, 4 profiles were identified: (1) minimal prevalence (ICU admission risk, 22% [18%–26%]), (2) cardiorenal/diabetes (27% [21%–34%]), (3) hematologic malignancy and transplant receipt (12% [6%–21%]), and (4) chronic pulmonary disease with home oxygen dependence (44% [25%–66%]). Conclusions: Distinct underlying condition profiles with varying risks of critical illness were observed among inpatients with RSV. These findings could support recognition of high-risk patients to inform RSV prevention strategies and suggest that the role of multimorbidity in severe RSV disease risk warrants further attention.


  • Modeling the Potential Impacts of Outpatient Antiviral Treatment in Reducing Influenza-Associated Hospitalizations in the United States

    by Sinead E Morris, Sarabeth M Mathis, Emily Reeves, Jessie R Chung, Rebecca K Borchering, Nathaniel M Lewis, Svetlana Masalovich, Shikha Garg, Timothy M Uyeki, A Danielle Iuliano, et al.

    Background: Seasonal influenza causes an estimated 120 000 to 710 000 hospitalizations annually in the United States. Treatment with antiviral medications, such as oseltamivir, can reduce risks of hospitalization among people with influenza-associated illness. The US Centers for Disease Control and Prevention recommends initiating antiviral treatment as soon as possible for outpatients with suspected or confirmed influenza who have severe or progressive illness or are at higher risk of influenza complications. Methods: We developed a probabilistic model to estimate the impact of antiviral treatment in reducing hospitalizations among US outpatients with influenza. Parameters were informed by seasonal influenza surveillance platforms and stratified by age group and whether individuals had a condition associated with higher risk of influenza complications. We modeled different scenarios for influenza antiviral effectiveness and outpatient testing and prescribing practices, then compared our results with a baseline scenario in which antivirals were not used. Results: Across the modeled scenarios, antiviral treatment resulted in 1215 to 14 184 fewer influenza-associated hospitalizations on average when compared with the baseline scenario (0.2%–2.7% reduction). The greatest effects occurred among adults aged ≥65 years and individuals with conditions associated with higher risk of influenza complications. Modeling 50% improvements in access to care, testing, prescribing, and treatment resulted in greater potential impacts, with over 71 000 (13.3%) influenza-associated hospitalizations averted on average compared to baseline. Conclusions: Our results support recommendations to prioritize outpatient antiviral treatment among older adults and others at higher risk of influenza complications. Improving access to prompt testing and treatment among outpatients with suspected influenza could reduce hospitalizations substantially.


  • Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024

    by Nathaniel M Lewis, Elizabeth J Harker, Seana Cleary, Yuwei Zhu, Carlos G Grijalva, James D Chappell, Jillian P Rhoads, Adrienne Baughman, Jonathan D Casey, Paul W Blair, et al.

    Background: The 2023–2024 influenza season included sustained elevated activity from December 2023 to February 2024 and continued activity through May 2024. Influenza A(H1N1), A(H3N2), and B viruses circulated during the season. Methods: During 1 September 2023 to 31 May 2024, a multistate sentinel surveillance network of 24 medical centers in 20 US states enrolled adults aged ≥18 years hospitalized with acute respiratory illness. Consistent with a test-negative design, cases tested positive for influenza viruses by molecular or antigen test, and controls tested negative for influenza viruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Vaccine effectiveness (VE) against influenza-associated hospitalization was calculated as (1 − adjusted odds ratio for vaccination) × 100%. Results: Among 7690 patients, including 1170 influenza cases (33% vaccinated) and 6520 controls, VE was 40% (95% confidence interval [CI], 31%–48%) with varying estimates by age: 18–49 years, 53% (95% CI, 34%–67%); 50–64 years, 47% (95% CI, 31%–60%); ≥ 65 years, 31% (95% CI, 16%–43%). Protection was similar among immunocompetent patients (40%; 95% CI, 30%–49%) and immunocompromised patients (32%; 95% CI, 7%–50%). VE was statistically significant against influenza B (67%; 95% CI, 35%–84%) and A(H1N1) (36%; 95% CI, 21%–48%) and crossed the null against A(H3N2) (19%; 95% CI, −8% to 39%). VE was higher for patients 14–60 days from vaccination (54%; 95% CI, 40%–65%) than >120 days (18%; 95% CI, −1% to 33%). Conclusions: During 2023–2024, influenza vaccination reduced the risk of influenza A(H1N1)- and influenza B-associated hospitalizations among adults; effectiveness was lower in patients vaccinated >120 days prior to illness onset compared with those vaccinated 14–60 days prior.


  • Open Access

    Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study

    by Nathaniel M Lewis, Elizabeth J Harker, Lauren B Grant, Yuwei Zhu, Carlos G Grijalva, James D Chappell, Jillian P Rhoads, Adrienne Baughman, Jonathan D Casey, Paul W Blair, et al.

    Background: Clinical guidelines recommend initiation of antiviral therapy as soon as possible for patients hospitalized with confirmed or suspected influenza. Methods: A multicenter US observational sentinel surveillance network prospectively enrolled adults (aged ≥18 years) hospitalized with laboratory-confirmed influenza at 24 hospitals during 1 October 2022–21 July 2023. A multivariable proportional odds model was used to compare peak pulmonary disease severity (no oxygen support, standard supplemental oxygen, high-flow oxygen/non-invasive ventilation, invasive mechanical ventilation, or death) after the day of hospital admission among patients starting oseltamivir treatment on the day of admission (early) versus those who did not (late or not treated), adjusting for baseline (admission day) severity, age, sex, site, and vaccination status. Multivariable logistic regression models were used to evaluate the odds of intensive care unit (ICU) admission, acute kidney replacement therapy or vasopressor use, and in-hospital death. Results: A total of 840 influenza-positive patients were analyzed, including 415 (49%) who started oseltamivir treatment on the day of admission, and 425 (51%) who did not. Compared with late or not treated patients, those treated early had lower peak pulmonary disease severity (proportional adjusted odds ratio [aOR]: 0.60, 95% confidence interval [CI]: .49–.72), and lower odds of intensive care unit admission (aOR: 0.24, 95% CI: .13–.47), acute kidney replacement therapy or vasopressor use (aOR: 0.40, 95% CI: .22–.67), and in-hospital death (aOR: 0.36, 95% CI: .18–.72). Conclusions: Among adults hospitalized with influenza, treatment with oseltamivir on day of hospital admission was associated reduced risk of disease progression, including pulmonary and extrapulmonary organ failure and death.


  • Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses — IVY Network, September 1, 2022–March 30, 2023

    by Nathaniel M. Lewis, Elizabeth J. Harker, Aleda Leis, Yuwei Zhu, H. Keipp Talbot, Carlos G. Grijalva, Natasha Halasa, James D. Chappell, Cassandra A. Johnson, Todd W. Rice, et al.


  • Open Access

    Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023

    by Jennifer DeCuir, Diya Surie, Yuwei Zhu, Adam S. Lauring, Manjusha Gaglani, Tresa McNeal, Shekhar Ghamande, Ithan D. Peltan, Samuel M. Brown, Adit A. Ginde, et al.

    Background: Assessments of COVID‐19 vaccine effectiveness are needed to monitor the protection provided by updated vaccines against severe COVID‐19. We evaluated the effectiveness of original monovalent and bivalent (ancestral strain and Omicron BA.4/5) COVID‐19 vaccination against COVID‐19‐associated hospitalization and severe in‐hospital outcomes.Methods: During September 8, 2022 to August 31, 2023, adults aged ≥ 18 years hospitalized with COVID‐19‐like illness were enrolled at 26 hospitals in 20 US states. Using a test‐negative case–control design, we estimated vaccine effectiveness (VE) with multivariable logistic regression adjusted for age, sex, race/ethnicity, admission date, and geographic region.Results: Among 7028 patients, 2924 (41.6%) were COVID‐19 case patients, and 4104 (58.4%) were control patients. Compared to unvaccinated patients, absolute VE against COVID‐19‐associated hospitalization was 6% (−7%–17%) for original monovalent doses only (median time since last dose [IQR] = 421 days [304–571]), 52% (39%–61%) for a bivalent dose received 7–89 days earlier, and 13% (−10%–31%) for a bivalent dose received 90–179 days earlier. Absolute VE against COVID‐19‐associated invasive mechanical ventilation or death was 51% (34%–63%) for original monovalent doses only, 61% (35%–77%) for a bivalent dose received 7–89 days earlier, and 50% (11%–71%) for a bivalent dose received 90–179 days earlier.Conclusion: Bivalent vaccination provided protection against COVID‐19‐associated hospitalization and severe in‐hospital outcomes within 3 months of receipt, followed by a decline in protection to a level similar to that remaining from previous original monovalent vaccination by 3–6 months. These results underscore the benefit of remaining up to date with recommended COVID‐19 vaccines.


  • Open Access

    Durability of protection from original monovalent and bivalent COVID-19 vaccines against COVID-19-associated hospitalization and severe in-hospital outcomes among adults in the United States — September 2022–August 2023

    by Jennifer DeCuir, Diya Surie, Yuwei Zhu, Adam S. Lauring, Manjusha Gaglani, Tresa McNeal, Shekhar Ghamande, Ithan D. Peltan, Samuel M. Brown, Adit A. Ginde, et al.

    Objective To evaluate the durability of protection provided by original monovalent and bivalent COVID-19 vaccination against COVID-19-associated hospitalization and severe in-hospital outcomes. Design Multicenter case-control design with prospective enrollment Setting 26 hospitals in 20 US states Participants Adults aged ≥18 years admitted to hospital with COVID-19-like illness from 8 September 2022 to 31 August 2023 Main outcome measures The main outcomes were absolute and relative vaccine effectiveness of original monovalent and bivalent COVID-19 vaccines against COVID-19-associated hospitalization and severe in-hospital outcomes, including advanced respiratory support (defined as receipt of high-flow nasal cannula, non-invasive ventilation, or invasive mechanical ventilation [IMV]) and IMV or death. Vaccine effectiveness was estimated using multivariable logistic regression, in which the odds of vaccination (versus being unvaccinated or receiving original monovalent vaccination only) were compared between COVID-19 case patients and control-patients. Bivalent vaccine effectiveness analyses were stratified by time since dose receipt. Results Among 7028 adults without immunocompromising conditions, 2924 (41.6%) were COVID-19 case patients and 4104 (58.4%) were control patients. Compared to unvaccinated patients, absolute vaccine effectiveness against COVID-19-associated hospitalization was 6% (-7% to 17%) for original monovalent doses only (median time since last dose [IQR] = 421 days [304–571]), 52% (39% to 61%) for a bivalent dose received 7–89 days earlier, and 13% (-10% to 31%) for a bivalent dose received 90–179 days earlier. Absolute vaccine effectiveness against COVID-19-associated advanced respiratory support was 31% (15% to 45%) for original monovalent doses only, 66% (47% to 78%) for a bivalent dose received 7–89 days earlier, and 33% (-1% to 55%) for a bivalent dose received 90–179 days earlier. Absolute vaccine effectiveness against COVID-19-associated IMV or death was 51% (34% to 63%) for original monovalent doses only, 61% (35% to 77%) for a bivalent dose received 7–89 days earlier, and 50% (11% to 71%) for a bivalent dose received 90–179 days earlier. Conclusion When compared to original monovalent vaccination only, bivalent COVID-19 vaccination provided additional protection against COVID-19-associated hospitalization and certain severe in-hospital outcomes within 3 months of dose receipt. By 3-6 months, protection from a bivalent dose declined to a level similar to that remaining from original monovalent vaccination only. Although no protection remained from original monovalent vaccination against COVID-19-associated hospitalization, it provided durable protection against severe in-hospital outcomes >1 year after receipt of the last dose, particularly against IMV or death. What is already known on this topic - On September 1, 2022, bivalent mRNA COVID-19 vaccination was recommended for US adults who had completed at least an original monovalent COVID-19 primary series. - Early estimates of bivalent vaccine effectiveness are available for the period soon after dose receipt; however fewer data exist on their durability of protection and effectiveness against severe outcomes. What this study adds - When compared to original monovalent vaccination only, bivalent mRNA COVID-19 vaccination provided additional protection against COVID-19-associated hospitalization and certain severe in-hospital outcomes within 3 months of dose receipt. By 3-6 months, protection from a bivalent dose declined to a level similar to that remaining from original monovalent vaccination only. - Although no protection remained from original monovalent vaccination against COVID-19-associated hospitalization, it provided durable protection against severe in-hospital outcomes >1 year after receipt of the last dose, particularly against invasive mechanical ventilation or death.